Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in Japan
Pembrolizumab monotherapy is a cost-effective option for the first-line treatment of advanced NSCLC with high programmed cell death ligand 1 expression in Japan, providing valuable health economic evidence for treatment selection.
Authors
- Mari Kogo (ORCID: https://orcid.org/0000-0001-7553-0872)
- Katsumi Tanaka (ORCID: https://orcid.org/0000-0001-6703-3139)
- Hiroo Ishida (ORCID: https://orcid.org/0000-0001-7441-7173)
- Hiroyuki Sakamaki
- Kazuki Tomura (ORCID: https://orcid.org/0009-0000-2318-2706)
- Shuichi Nawata (ORCID: https://orcid.org/0000-0002-2193-9899)
Institutions
- SHOWA Medical University (JP)
- SHOWA Medical University Northern Yokohama Hospital (JP)
- SHOWA Medical University Hospital (JP)
- Kanagawa University of Human Services (JP)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1007/s11096-024-01826-7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00